Free Trial
NASDAQ:SLGL

Sol-Gel Technologies Q4 2023 Earnings Report

Sol-Gel Technologies logo
$15.99 +1.38 (+9.45%)
Closing price 03:54 PM Eastern
Extended Trading
$15.70 -0.29 (-1.81%)
As of 06:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sol-Gel Technologies EPS Results

Actual EPS
-$1.70
Consensus EPS
-$1.60
Beat/Miss
Missed by -$0.10
One Year Ago EPS
N/A

Sol-Gel Technologies Revenue Results

Actual Revenue
$0.45 million
Expected Revenue
$0.27 million
Beat/Miss
Beat by +$180.00 thousand
YoY Revenue Growth
N/A

Sol-Gel Technologies Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Wednesday, March 13, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

Sol-Gel Technologies' Q4 2024 earnings is scheduled for Friday, August 15, 2025, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Sol-Gel Technologies Earnings Headlines

The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”
Sol-Gel Technologies Ltd. (SLGL) - Yahoo Finance
SLGL Sol-Gel Technologies Ltd. - Seeking Alpha
Sol-Gel Technologies Ltd
See More Sol-Gel Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sol-Gel Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sol-Gel Technologies and other key companies, straight to your email.

About Sol-Gel Technologies

Sol-Gel Technologies (NASDAQ:SLGL), together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

View Sol-Gel Technologies Profile

More Earnings Resources from MarketBeat